Asset Details
Do you wish to reserve the book?
Methylnaltrexone for the treatment of opioid-induced constipation
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Methylnaltrexone for the treatment of opioid-induced constipation
Do you wish to request the book?
Methylnaltrexone for the treatment of opioid-induced constipation
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Methylnaltrexone for the treatment of opioid-induced constipation
2013
Overview
Opioids are the drugs of choice for treating moderate-to-severe pain, especially for patients in the end stage of cancer or other advanced illnesses, and also in critical care or for the treatment of chronic pain. Side effects such as nausea, pruritus, dizziness and constipation have to be controlled in order to use these drugs to their full potential. Opioid-induced bowel syndrome and constipation caused by activation of μ-receptors in the gut can have such distressing effects that some patients prefer to forego adequate pain control. Methylnaltrexone is a μ-opioid receptor antagonist that, unlike naltrexone or naloxone, does not pass the blood-brain barrier, and therefore does not impair the centrally mediated analgesic effect of opioids. It is licensed for the treatment of opioid-induced constipation in palliative care in more than 50 countries. This article presents practically relevant pharmacological data, basic research results and evidence from clinical research about methylnaltrexone, and outlines potential future therapeutic options for this promising drug.
Publisher
Taylor & Francis,Expert Reviews Ltd,Informa Healthcare
Subject
Analgesics, Opioid - adverse effects
/ Complications and side effects
/ Constipation - chemically induced
/ Humans
/ Naloxone - analogs & derivatives
/ Narcotic Antagonists - adverse effects
/ Narcotic Antagonists - pharmacokinetics
/ Narcotic Antagonists - therapeutic use
/ opioid
/ Opioids
/ peripherally acting μ-opioid receptor antagonist
/ Quaternary Ammonium Compounds - adverse effects
/ Quaternary Ammonium Compounds - pharmacokinetics
/ Quaternary Ammonium Compounds - therapeutic use
/ Receptors, Opioid, mu - drug effects
